Clinical Trials Logo

Clinical Trial Summary

The main obstacle to achieving R0 resection in future liver remnant(FLR) deficient liver cancer is the inability to retain sufficient FLR to avoid postoperative liver failure. From the initial portal vein embolization(PVE), to the later ALPPS, this problem has been solved to some extent. However, both have their own shortcomings. The effect of liver hyperplasia after PVE is poor and the waiting time is long. The incidence of complication and mortality after ALPPS is always the focus of controversy. In recent years, LVD has emerged, combining PVE and HVE in the one operation. This topic will conduct a clinical controlled study of PVE and LVD.


Clinical Trial Description

n/a


Study Design


NCT number NCT05457374
Study type Interventional
Source Anhui Provincial Hospital
Contact
Status Recruiting
Phase N/A
Start date March 1, 2022
Completion date March 1, 2025